J. Edward Puzas, a professor of orthopaedics at the University of Rochester School of Medicine and Dentistry, agreed that better studies are needed before doctors and patients can make conclusions about the link between these drugs and osteonecrosis of the jaw.
"Identifying all patients who are on alendronate and then reporting on the incidence of [osteonecrosis of the jaw] in this group does not implicate alendronate in the causation of the [condition]," he said.
"Given the concern of dental community in the use of bisphosphonates, I think a carefully designed cohort study to settle the issue is warranted."
ABC News' Audrey Grayson and Michelle Schlief contributed to this report.
Do you have more information about this topic? If so, please click here to contact the editors of ABC News.
